An FDA advisory committee is reviewing Moderna’s mRNA-based influenza vaccine, dubbed mFlusiva, in a meeting that is intended to inform a future FDA decision. Multiple outlets report that the vaccine is being considered for use by people ages 50 and older ahead of the upcoming winter flu season. The deliberations are focused on the vaccine’s data and whether it meets the standards for safety and effectiveness required for approval.
The reviews also emphasize that mFlusiva uses the same general mRNA technology that was central to COVID-19 vaccines, marking it as a first-of-its-kind approach for an influenza shot using this platform. Reporting describes the advisory committee meeting as a step in the approval process rather than the final decision. Following the panel’s discussion and recommendation, FDA would consider the committee input and the evidence as it moves toward a potential authorization decision in time for the flu season.
